Ab­b­Vie, rid­ing the Aduhelm af­ter­glow, hand­picks be­ta amy­loid drug for fur­ther R&D as it bails on tau

Al­though shroud­ed in con­tro­ver­sy, the FDA’s ap­proval of Bio­gen’s Aduhelm for Alzheimer’s dis­ease has opened the flood­gates for oth­er drug­mak­ers buy­ing in on the an­ti-amy­loid hy­poth­e­sis un­der­scor­ing the drug’s suc­cess. You can now count drug gi­ant Ab­b­Vie among them.

On an earn­ings call with an­a­lysts Fri­day, Ab­b­Vie $AB­BV re­vealed its plans to ad­vance a hand­picked be­ta amy­loid tar­get­ing mol­e­cule for Alzheimer’s dis­ease while aban­don­ing de­vel­op­ment of its Phase II tau pro­gram AB­BV-8E12.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER